Loss of response to long-term infliximab therapy in children with Crohn's disease

Oliver Gouldthorpe; Anthony Catto-Smith; George Alex; Dianne M Simpson

doi:10.3390/ph6101322

Loss of response to long-term infliximab therapy in children with Crohn's disease

Oliver Gouldthorpe, Anthony Catto-Smith, George Alex, Dianne M Simpson

Paediatrics Monash Health

Research output: Contribution to journal › Article › Research › peer-review

12 Citations (Scopus)

Abstract

Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.

Original language	English
Pages (from-to)	1322 - 1334
Number of pages	13
Journal	Pharmaceuticals
Volume	6
DOIs	https://doi.org/10.3390/ph6101322
Publication status	Published - 2013

Access to Document

10.3390/ph6101322

RM sElocation

Cite this

@article{ceb0aba1592745cba2b5587318a3d6ba,

title = "Loss of response to long-term infliximab therapy in children with Crohn's disease",

abstract = "Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.",

author = "Oliver Gouldthorpe and Anthony Catto-Smith and George Alex and Simpson, {Dianne M}",

year = "2013",

doi = "10.3390/ph6101322",

language = "English",

volume = "6",

pages = "1322 -- 1334",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "MDPI AG",

}

TY - JOUR

T1 - Loss of response to long-term infliximab therapy in children with Crohn's disease

AU - Gouldthorpe, Oliver

AU - Catto-Smith, Anthony

AU - Alex, George

AU - Simpson, Dianne M

PY - 2013

Y1 - 2013

N2 - Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.

AB - Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817600/pdf/pharmaceuticals-06-01322.pdf

U2 - 10.3390/ph6101322

DO - 10.3390/ph6101322

M3 - Article

VL - 6

SP - 1322

EP - 1334

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

ER -